About Genoa Psychiatric Pharmacy Courses

Genoa’s psychiatric pharmacy courses are offered in conjunction with the American Association of Psychiatric Pharmacists (AAPP), a membership association serving and driven by psychiatric pharmacists. These modules will close 12/31/2025. You can anticipate that each module will take you between 1 to 3 hours to complete depending on your learning style and preferences. Each module has a required examination. A score of 70% is required to successfully complete each exam. You are allowed one test and one re-test per course, for a maximum of 2 attempts.

For more background and instructions, read the Participant Packet.

If at any time you have questions, please contact Genoa-U@genoahealthcare.com.

Technical access issues should be addressed to info@aapp.org.

Get Started!

Topic
Anxiety and Anxiety-Related Disorders
(2 ACPE hours)

ACPE #0284-0000-24-002-H01-P (Knowledge)
Author: Robin Hieber, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for anxiety and anxiety-related disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for anxiety and anxiety-related disorders.
  2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of anxiety and anxiety-related disorders.
  3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of anxiety and anxiety-related disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in anxiety and anxiety-related disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for anxiety and anxiety-related disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of anxiety and anxiety-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with anxiety and anxiety-related disorders.
Bipolar Disorder
(1.5 ACPE hours)

ACPE #0284-0000-24-004-H01-P (Knowledge)
Author: Jeremy Daniel, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for bipolar disorder, including the list of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for bipolar disorder.
  2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of bipolar disorder.
  3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of bipolar disorder.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in bipolar disorder.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for bipolar disorder.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of bipolar disorder in special populations (i.e., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with bipolar disorder.
Depression
(1.5 ACPE hours)

ACPE #0284-0000-24-005-H01-P (Knowledge)
Author: Sarah Grady, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for depression, including the listing of medications, substances, and diseases that can cause or worsen depression.
  2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of depression.
  3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of depression.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in depression.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for depression.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of depression in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with depression.
  10. Explain the components of suicide risk assessment.
  11. Describe the determination of levels of suicide risk.
Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders
(1 ACPE hour)

ACPE #0284-0000-24-007-H01-P (Knowledge)
Author: Sandra Mullen, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, and conduct disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for these disorders.
  2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes:
    1. Down Syndrom
    2. Prader-Willi Syndrome
    3. Fragile X Syndrome
    4. Klinefelter’s Syndrome
    5. Rett's Syndrome
  10. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Schizophrenia Spectrum and Other Psychotic Disorders
(2 ACPE hours)

ACPE #0284-0000-24-011-H01-P (Knowledge)
Author: Charles Caley, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for schizophrenia spectrum, other psychotic disorders, and movement disorders, including the lists of medications, substances, and diseases that can cause or worsen symptoms for these disorders.
  2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of schizophrenia spectrum, other psychotic disorders, and movement disorders.
  3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of schizophrenia spectrum, other psychotic disorders, and movement disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in schizophrenia spectrum, other psychotic disorders, and movement disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and practice implications for schizophrenia spectrum, other psychotic disorders, and movement disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of schizophrenia spectrum, other psychotic disorders, and movement disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with schizophrenia spectrum, other psychotic disorders, and movement disorders.
  10. Describe provider behaviors and responses, environmental responses, and de-escalation techniques useful for calming agitated patients.
Sleep-Wake Disorders
(1.5 ACPE hours)

ACPE #0284-0000-24-012-H01-P (Knowledge)
Author: Megan Maroney, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for sleep-wake disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for sleep-wake disorders.
  2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of sleep-wake disorders.
  3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of sleep-wake disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions [including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for drugs used in sleep-wake disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for sleep-wake disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of sleep-wake disorders in special populations (e.g., pregnancy/lactation, children, and elderly patients).
  9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with sleep-wake disorders.
Substance-Related Disorders
(1.5 ACPE hours)

ACPE #0284-0000-24-013-H01-P (Knowledge)
Author: Erika Titus-Lay, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for substance-related disorders, including the listing of medications, substances, and diseases that can cause or worsen the psychiatric symptoms for substance-related disorders.
  2. Explain the use of common rating scales for the screening, diagnosis, and monitoring of substance-related disorders.
  3. Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of substance-related disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) and withdrawal symptoms for substances used in substance-related disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for substance-related disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of substance-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about medication therapy and organizations that advocate and provide resources for individuals with substance-related disorders.